Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Carlos U. Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Hans Gerdes, Michael K. Gibson, Patrick Grierson, Garima Gupta, Wayne L. Hofstetter, David H. Ilson, Shadia I. Jalal, Sunnie S. Y. Kim, Lawrence Kleinberg, Samuel J. Klempner, Jill Lacy, Byrne Lee, Frank Licciardi, Shane Lloyd, Quan P. Ly, Karen Matsukuma, Michael McNamara, Ryan P. Merkow, Aaron M. Miller, Sarbajit Mukherjee, Mary F. Mulcahy, Kyle A. Perry, José M. Pimiento, Deepti Reddi, Scott I. Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Nataliya V. Uboha, Zev A. Wainberg, Christopher G. Willett, Yanghee Woo, Harry H. Yoon, Nicole R. McMillian, MaryElizabeth Stein
Abstract
Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.